Clinical Trial Update: EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of EMD 525797 in asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• EMD 525797

Snippet

Sponsor: EMD Serono | Conditions: Prostate Cancer Metastatic | Phase 2 | Status: COMPLETED | Results posted: 2015-12-14